CD274 and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma (ESCC), agents targeting the PD‐1/PD‐L1 pathway have demonstrated encouraging activity; nivolumab is approved in the United States for patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine and platinum‐based chemotherapy11; pembrolizumab is approved for patients with recurrent locally advanced or metastatic ESCC with disease progression after ≥1 prior line of systemic therapy and whose tumors express high PD‐L1.12